Clinitech Laboratory’s shares debuted at Rs 115 on BSE SME, indicating a 20% premium over the issue price of Rs 96. The Rs 5.78 crore SME IPO was available for subscription from July 25 to July 29, 2024, at a price of Rs 96 per share.
It consisted mainly of a fresh issue of 6.02 lakh shares, with no offer-for-sale component. The IPO had a strong response, with an aggregate subscription rate of 38.96 times. Retail investors were quite interested, subscribing 49.91 times; other investors were very enthusiastic, subscribing 23.28 times.
The company is a renowned provider of diagnostic and healthcare testing, with eight diagnostic centres situated in and around Thane and Navi Mumbai. It has been in the diagnostic industry for thirty years.
With the use of sophisticated equipment and modern technology, its facilities perform over 300,000 tests a year in recognized NABL (National Accreditation Board for Testing and Calibration Laboratories) laboratories.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered as financial advice. The data and figures presented are based on publicly available information and may be subject to change. Before making any investment decisions, it is recommended to conduct thorough research, consult with financial advisors, and consider your individual investment goals and risk tolerance. The author and publisher of this article do not assume any responsibility for any investment decisions made based on the information provided.